Article

A phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma

2020-07-24

Abstract excerpt

<title>Abstract</title> <p><bold>Background </bold>Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next-generation anthracycline that is commonly used to treat lung cancer. We conducted a phase II trial of this drug in patients with previously treated M...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 289346a9-5ded-5544-adec-dbafce15ef1e
DOI: 10.21203/rs.3.rs-42543/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesotheliomaDOI 10.21203/rs.3.rs-42543/v1Read

[Malignant pleural mesothelioma: 2013 state of the art].Semantic proximity Read

Multimodality treatment of malignant pleural mesotheliomaSemantic proximity Read

Patient-derived organoids from malignant pleural effusion to explore for alternative therapies in thoracic tumorsSemantic proximity Read

Intrapleural injection of Folactis promotes regression of malignant pleural effusion: a case of malignant pleural mesothelioma and the review of literaturesSemantic proximity Read

Management of malignant pleural mesothelioma.Semantic proximity Read

Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.Semantic proximity Read

Case report: targeted therapy of malignant pleural mesothelioma with anaplastic lymphoma kinase receptor tyrosine kinase gene fusion mutation by crizotinib.Semantic proximity Read

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesotheliomaSemantic proximity Read

A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.Semantic proximity Read

Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patientsSemantic proximity Read

Integrating Data from Multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort studySemantic proximity Read

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.Semantic proximity Read